2015 ATA Clinical Management Guidelines on Medullary Thyroid Cancer and Pediatric Thyroid Cancer - Highlights, Consensus and Controversies

San Diego, CA US
March 4, 2015

The symposium entitled “2015 American Thyroid Association (ATA) Clinical Management Guidelines on Medullary Thyroid Cancer (MTC) and Pediatric Thyroid Cancer—Highlights, Controversies and Consensus”  will feature important discussions on significant revisions to the MTC guidelines and review the inaugural pediatric thyroid nodule and cancer guidelines, utilizing a panel of experts to highlight the “real world” applications of the guidelines.  The symposium will also allow time for audience participation in discussion of these new guidelines.

Target Audience

This continuing medical education activity should be of substantial interest to the community of endocrinologists, internists, surgeons, basic scientists, nuclear medicine scientists, pathologists, trainees, nurses, physician assistants and other health care professionals who wish to broaden and update their knowledge on thyroid nodules, differentiated thyroid cancer and the current ATA guidelines surrounding these topics.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Describe major changes in the 2015 ATA Guidelines on Medullary Thyroid Cancer (MTC) and how these should be applied in clinical practice
  • Understand the inaugural ATA Guidelines on Pediatric Thyroid Nodules and Differentiated Thyroid Cancer (DTC) and how these guidelines differ from adult recommendations
  • Describe the risk of malignancy and the appropriate evaluation and treatment in children with thyroid nodules
  • Identify appropriate surgical approaches that reduce long-term recurrence while minimizing harm to the voice and parathyroid function in both MTC and pediatric DTC
  • Apply risk stratification to post-operative staging to tailor radioactive (RAI) therapy, initial TSH goals, and monitoring in children with DTC
  • Identify children who will and who may not benefit from RAI treatment and discuss approaches to the use of RAI to treat pulmonary metastases
  • Apply appropriate monitoring techniques to patients with MTC who have persistently detectable calcitonin levels
  • Identify patients with advanced and metastatic MTC who are appropriate candidates for monitoring, directed therapies, and systemic therapies
  • Review the management of patients with multiple endocrine neoplasia type 2 (MEN2), including the timing of prophylactic thyroidectomy and management of pheochromocytoma and hyperparathyroidism in this population
  • Describe the ethical considerations surrounding genetic testing in MTC and MEN2

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Pediatric Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credits
  • 4.50 CME Certificate of Participation
Course opens: 
Course expires: 
Event starts: 
03/04/2015 - 12:00pm
Event ends: 
03/04/2015 - 5:30pm
San Diego Convention Center
111 W Harbor Drive
San Diego, CA 92101
United States

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer Faculty

Andrew J. Bauer, MD, Co-Chair
Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Steven G. Waguespack, MD, Co-Chair
University of Texas M.D. Anderson Cancer Center, Houston, Texas

Salvatore Benvenga, MD
Policlinico Universitario di Messina, Italy

Catherine A. Dinauer, MD
Yale University School of Medicine, New Haven, Connecticut

Markus Luster, MD
University of Marburg and University Hospital, Marburg, Germany

Geoffrey B. Thompson, MD
Mayo Clinic, Rochester, Minnesota

Guidelines for the Management of Medullary Thyroid Carcinoma Faculty

Samuel A. Wells, Jr., MD, Chair
National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Douglas B. Evans, MD
Medical College of Wisconsin, Milwaukee, Wisconsin

Robert F. Gagel, MD
University of Texas M. D. Anderson Cancer Center, Houston, Texas

Bruce G. Robinson, MD
University of Sydney, Sydney, Australia

M. Sara Rosenthal, PhD
University of Kentucky, Lexington, Kentucky

Steven G. Waguespack, MD
University of Texas M.D. Anderson Cancer Center, Houston, Texas


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. 

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity: 

Bruce Robinson, MD: Advisory Board Member, AstraZeneca, Bayer, Inc.

The following faculty reported no relevant financial relationships:

Andrew Bauer, MD; Salvatore Benvenga, MD; Catherine Dinauer, MD; Douglas Evans, MD; Robert Gagel, MD; Markus Luster, MD, PhD; M. Sara Rosenthal, PhD; Geoffrey Thompson, MD; Steven Waguespack, MD; Samuel Wells, MD

The following Endocrine Society SPC member who reviewed content for this activity reported no relevant financial relationships:

Larry Fox, MD

The following SPC members reported relevant financial relationships:

Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Anton Luger, MD: Advisory Board, Investigator and Speaker, Novo Nordisk; Advisory Board and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi
Andrea Utz, MD, PhD: Advisory Board, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: 

Jeffrey Boord, MD, MPH; Michael Irwig, MD; Connie Newman, MD

Endocrine Society and American Thyroid Association staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 4.50 AMA PRA Category 1 Credits
  • 4.50 CME Certificate of Participation